Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keijzer, A
Right arrow Articles by van de Loosdrecht, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keijzer, A
Right arrow Articles by van de Loosdrecht, A.
Haematologica, Vol 91, Issue 12_Suppl, ECR51-ECR51
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha

A Keijzer, P van der Valk, GJ Ossenkoppele, and AA van de Loosdrecht

VU-University Medical centre Amsterdam, department of haematology, de Boelelaan 1117, BR 240,1081 HV, Amsterdam, The Netherlands. A.Keijzer@vumc.nl

Accelerated programmed cell death or apoptosis appears to play an important role in the pathogenesis of myelodysplasia. As overexpression of TNF-alpha has been described to induce cell death in myelodysplasia, treatment with anti-TNF-alpha is currently being explored. Caution is needed because of an increased risk of opportunistic infection during anti-TNF-alpha treatment. We here describe a patient who was treated with anti-TNF-alpha for low risk myelodysplasia and died of invasive mucormycosis.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.